The channel looks into peptides used outside their approved purposes and walks through its findings. Watch for the sourcing behind each claim.
Recap by typeshit. Full story at The Science of Self-Care.
Half of people with diabetes for 10 years or more said they were very satisfied on a GLP-1. Gen Z users were the most likely to stop and restart treatment.
64% of current users faced some negative reaction. Men, BIPOC respondents and the newly diagnosed reported it most, while 69% of boomers felt none.
The workflow uses glutathione or sulfatase triggers to target organelles and tumors in mice, and the authors say it takes 92 to 115 days to run.
A University of Pennsylvania mouse study found on-off GLP-1 use left mice 20 per cent heavier than those kept on the drug, and doctors warn human effects are unknown.
Researchers from WCVM and USask Medicine used the Canadian Light Source to study how an antimicrobial peptide forms a pore structure.
An unpublished study of 3,855 women presented at the Menopause Society meeting found the gap held for semaglutide users. Experts caution it shows an association only.
Loading…